This is the authors' abstract. We don't add key points for this paper.
The A/A genotype, which may represent a CYP1A2 high inducibility genotype, may either be a direct cause of increased CYP1A2 activity, or be genetically linked to polymorphisms conferring high inducibility. Further studies are needed to define the role of this polymorphism on the pharmacokinetics of drugs metabolised by CYP1A2 and in the activation of carcinogens.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Sachse et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: